Pfizer Inc. (NYSE:PFE) Shares Sold by Richard C. Young & CO. LTD.

Richard C. Young & CO. LTD. trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 4.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 432,965 shares of the biopharmaceutical company’s stock after selling 19,042 shares during the quarter. Richard C. Young & CO. LTD.’s holdings in Pfizer were worth $11,487,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC bought a new position in Pfizer in the 4th quarter valued at about $26,000. Gladius Capital Management LP lifted its stake in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 38,015 shares during the period. Teachers Insurance & Annuity Association of America bought a new position in shares of Pfizer in the third quarter valued at approximately $35,000. Joseph Group Capital Management increased its stake in shares of Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 771 shares during the period. Finally, Sugar Maple Asset Management LLC bought a new stake in Pfizer during the fourth quarter worth approximately $43,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the topic of several research analyst reports. Wolfe Research started coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Citigroup dropped their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Trading Down 0.3 %

Shares of PFE stock opened at $25.76 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business’s 50 day moving average is $26.28 and its two-hundred day moving average is $27.74. The company has a market cap of $145.96 billion, a PE ratio of 18.27, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the business posted $0.10 earnings per share. The firm’s revenue was up 24.7% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.68%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is presently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.